Sanofi

Sanofi-aventis

Other

Sanofi Pasteur Inc.

Jean-marc Herbert

Marie-francoise Bordes

Francoise Bono

Alain Badorc

Nathalie Guillo

Marie-Francoise Bordes

Jean-Marc Herbert

Alexandre Benazet

Jean-Pierre Maffrand

Gilbert Lassalle

Olivier Duclos

Bachra Rokbi

Jean-Michel Foidart

Philippe Talaga

Chantal Alcouffe

Noëlle Mistretta

Gilles Anne-Archard

Françoise Bono

Pierre Fons

Agnes Noel

Valérie Vin

Valérie Martin

Jean-Marie Rakic

Marie-Line Clary-Ceccato

Pierre-Alexandre Driguez

Karim Macary

Jacob-Alsboek Olsen

Valérie Viv

The invention relates to a conjugate of a saccharide covalently bound to a carrier protein, wherein the saccharide comprises repetitive units of 1,5 ribitol phosphate in which all the ribitol residues are substituted by N-acetyl D-glucosaminyl residues at the 4-position, and wherein said N-acetyl D-glucosaminyl residues are exclusively in anomeric configuration &#x3b1; or are exclusively in anomeric configuration &#x3b2; and wherein the carrier protein provides at least one epitope to the conjugate which is recognized by T helper lymphocytes.

Immunogenic compositions against

The invention related to pyrazolonaphthyridinone derivatives of formula (I) to their preparation and to their therapeutic use as selective inhibitors of type 2 methionine aminopeptidase (hMETAP2). 

Pyrazolonaphthyridinone derivatives as MetAP2 inhibitors (methionine aminopeptidase type-2)

The invention relates to novel heterocyclic compounds which are pyrazolopyridine derivatives that induce FGFR dimerization, having the general formula: M-L-M2 in which M and M2, which may be identical or different, each represent, independently of one another, a monomer unit M and L represents a linker group which links Mand Mcovalently with the monomer unit which follows (Formula M). Process for the preparation thereof and therapeutic use thereof. 

Substituted dimeric quinazoline-2,4-diones as FGF receptor agonists

The invention relates to compounds corresponding to formula (I) in which R1, R2 and R3 are as defined in Claim, and also to the process for preparing them and to their therapeutic use.

Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof

FGF receptor agonist compounds corresponding to the general formula: M1-L-M2 are disclosed in which M1 and M2, which may be identical or different, each represent, independently of one another, a monomer unit M, and L represents a linker group, wherein the monomer unit is of the general formula I. 

FGF-receptor agonist dimeric compounds

The invention relates to novel heterocyclic compounds which are pyrazolopyridine derivatives that induce fibroblast growth factor receptor (FGFR) dimerization, having the general formula: M-L-Min which Mor M, which may be identical or different, each represent, independently of one another, a monomer unit M and L represents a linker group which links Mand Mcovalently with the monomer unit which follows: Process for the preparation thereof and therapeutic use thereof. 

FGF receptor (FGFR) agonist dimeric compounds, process for the preparation thereof and therapeutic use thereof

The present invention thus relates to the use of 1,2,3-substituted indolizine derivatives in the preparation of medicaments of use in the treatment of diseases related to pathological choroidal angiogenesis, which derivatives correspond to the following general formula (I): 

Use of FGF inhibiting substituted 1,2,3 indolizine derivatives in the preparation of medicaments which can be used to treat diseases linked to pathological choroidal angiogenesis

The present invention relates to novel 1,2,3-substituted indolizine derivative which are inhibitors of fibroblast growth factors, to methods or preparing such derivatives, to pharmaceutical compositions comprising such derivatives, and to methods of treatment comprising such derivatives.

1,2,3-substituted indolizine derivatives, inhibitors of FGFs, method for preparing them and pharmaceutical compositions containing them

The invention is directed to a compound of formula I, wherein R, R, R, Rand Rare as defined herein, or a pharmaceutically acceptable salt thereof, and its pharmaceutically composition, preparation and uses as an inhibitor of FGFs (fibroblast growth factors).

Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives

Compounds of formula I or salts thereof: in which

1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same

Growing community of inventors

Paris, France

Nathalie Guillo